INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2024 and provides a business update. Q3 2024 and Recent Corporate Highlights   DN-TNF Platform Highlights (XPro™): Announced completion enrollment for its Phase 2 Alzheimer’s Disease (“A ...